NCT03370588View on ClinicalTrials.gov

The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

May 27, 2019

Study Completion Date

May 27, 2019

Conditions
Colon Cancer
Interventions
DRUG

dexmedetomidine

Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.

DRUG

Normal saline

Group B: Saline infusion during same time period.

Trial Locations (1)

03722

Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03370588 - The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial | Biotech Hunter | Biotech Hunter